2/28
01:30 am
tars
Low
Report
2/27
06:26 am
tars
Tarsus Pharmaceuticals (TARS) was downgraded by Zacks Research from "strong-buy" to "hold".
Low
Report
Tarsus Pharmaceuticals (TARS) was downgraded by Zacks Research from "strong-buy" to "hold".
2/26
04:30 pm
tars
Tarsus to Participate in Upcoming Investor Conferences
Low
Report
Tarsus to Participate in Upcoming Investor Conferences
2/26
12:42 am
tars
Has The Market Rerated Tarsus Pharmaceuticals (TARS) Too Cautiously After XDEMVY Adoption Headlines? [Yahoo! Finance]
Medium
Report
Has The Market Rerated Tarsus Pharmaceuticals (TARS) Too Cautiously After XDEMVY Adoption Headlines? [Yahoo! Finance]
2/25
12:58 pm
tars
Tarsus Pharmaceuticals (TARS) had its price target raised by Oppenheimer Holdings, Inc. from $95.00 to $105.00. They now have an "outperform" rating on the stock.
Medium
Report
Tarsus Pharmaceuticals (TARS) had its price target raised by Oppenheimer Holdings, Inc. from $95.00 to $105.00. They now have an "outperform" rating on the stock.
2/25
09:39 am
tars
Tarsus Pharmaceuticals (TARS) had its price target raised by Guggenheim from $87.00 to $90.00. They now have a "buy" rating on the stock.
Low
Report
Tarsus Pharmaceuticals (TARS) had its price target raised by Guggenheim from $87.00 to $90.00. They now have a "buy" rating on the stock.
2/24
12:43 pm
tars
Tarsus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Tarsus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/24
12:21 am
tars
Tarsus Pharmaceuticals Inc (TARS) Q4 2025 Earnings Call Highlights: Strong Financial ... [Yahoo! Finance]
Low
Report
Tarsus Pharmaceuticals Inc (TARS) Q4 2025 Earnings Call Highlights: Strong Financial ... [Yahoo! Finance]
2/23
09:12 pm
tars
Tarsus Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Tarsus Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
2/23
04:05 pm
tars
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
High
Report
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements
2/18
08:30 am
tars
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
Low
Report
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
2/17
04:30 pm
tars
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
Low
Report
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026
2/5
09:12 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "neutral" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/27
05:58 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/24
05:10 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/15
06:06 am
tars
While shareholders of Tarsus Pharmaceuticals (NASDAQ:TARS) are in the black over 3 years, those who bought a week ago aren't so fortunate [Yahoo! Finance]
Low
Report
While shareholders of Tarsus Pharmaceuticals (NASDAQ:TARS) are in the black over 3 years, those who bought a week ago aren't so fortunate [Yahoo! Finance]
12/11
06:29 am
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
12/8
06:06 pm
tars
Tarsus Pharmaceuticals (NASDAQ:TARS) was given a new $100.00 price target on by analysts at Barclays PLC.
Medium
Report
Tarsus Pharmaceuticals (NASDAQ:TARS) was given a new $100.00 price target on by analysts at Barclays PLC.
12/5
09:32 am
tars
Can Tarsus Pharmaceuticals Stock Still Offer Value After Its 48% 2025 Rally? [Yahoo! Finance]
Low
Report
Can Tarsus Pharmaceuticals Stock Still Offer Value After Its 48% 2025 Rally? [Yahoo! Finance]